Xeris Biopharma Holdings (XERS) Cash from Operations (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Cash from Operations came in at 9870000.0 in Q1 2026, up 198.39% YoY from 3307696.45 in Q1 2025, and down 50.76% on a QoQ basis from 20043000.0 in Q4 2025.
Xeris Biopharma Holdings (XERS) Cash from Operations (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Cash from Operations data on file, last reported at 9870000.0 in Q1 2026.
- Quarterly Cash from Operations rose 198.39% year-over-year to 9870000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 48527000.0 (up 281.69% YoY) and the FY2025 annual result came in at 28626000.0, up 177.41% from the prior year.
- Cash from Operations declined to 9870000.0 in Q1 2026, from 20043000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 20043000.0 in Q4 2025 to a low of 48409000.0 in Q1 2022.
- A 5-year average of 8729352.94 and a median of 10348000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 102.07% — and 2025, when it soared 914.84%.
- Tracing XERS's Cash from Operations over 5 years: stood at 16119000.0 in 2022, then jumped by 146.35% to 7471000.0 in 2023, then slumped by 73.56% to 1975000.0 in 2024, then soared by 914.84% to 20043000.0 in 2025, then slumped by 50.76% to 9870000.0 in 2026.
- The last three Cash from Operations figures came in at 9870000.0 (Q1 2026), 20043000.0 (Q4 2025), and 18432000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 8.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.26 Mn |
| Jun 30, 2026 | 8.26 Mn |
| Mar 31, 2026 | 9.87 Mn |
| Mar 31, 2026 | 9.87 Mn |
| Dec 31, 2025 | 20.04 Mn |
| Dec 31, 2025 | 20.04 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Sep 30, 2025 | 18.43 Mn |
| Jun 30, 2025 | 182,000.00 |
| Jun 30, 2025 | 182,000.00 |
| Mar 31, 2025 | -10.03 Mn |
| Mar 31, 2025 | -10.03 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Jun 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -10.35 Mn |
| Mar 31, 2024 | -20.30 Mn |
| Mar 31, 2024 | -20.30 Mn |